SURMOUNT-1 Tirzepatide The pivotal tirzepatide trial, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity to tirzepatide 5 mg, 10 mg, 15 mg or placebo for 72 weeks
Semaglutide addresses these downstream effects directly
Consultation fee: $100 (applied toward your service if you move forward
While skipped periods can be caused by Ozempic-related weight loss, they can also signal something else
Important safety note: The FDA advises against using quinine or quinine-containing products (including tonic water) for leg cramps due to serious safety concerns
Patients who have a current or past diagnosis of certain medical conditions may not be candidates for semaglutide, including those diagnosed with: Pancreatitis Thyroid cancer Type I diabetes Severe episodes of low blood sugar Gallbladder issues Multiple endocrine neoplasia syndrome type 2 (MEN2) It is important to note that a patient with one or more of these conditions may still qualify for a semaglutide weight loss program